Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only?

William Arthur Cliby, Giovanni D. Aletti, Timothy O. Wilson, Karl C. Podratz

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Background.: Stage IIIC epithelial ovarian cancer is generally associated with upper abdominal tumor implants of greater than 2 cm and carries a grave prognosis. A subset of patients is upstaged to Stage IIIC because of lymph node metastases, in which prognosis is not well defined. We undertook this study to describe the clinical behavior of occult Stage IIIC. Methods.: All consecutive patients found to have Stage IIIC epithelial ovarian cancer during a 9-year period (1994-2002) were analyzed for surgical procedures, pathology, and disease-free (DFS) and overall survival (OS). Results.: Thirty-six patients were upstaged to Stage IIIC by virtue of positive nodes. Nine had small volume upper abdominal disease (IIIA/B before upstaging), 15 had disease limited to the pelvis and 12 had disease confined to the ovaries. 32/36 patients had no gross residual disease at the conclusion of surgery. The 5-year DFS and OS survivals were 52% and 76% respectively, for all patients. We observed no significant difference in outcomes between patients upstaged from IIIA/B versus I-II stage disease. The outcomes were superior to a control group of patients cytoreduced to either no gross RD or RD < 1 cm, who had large volume upper abdominal disease at beginning of surgery (p < 0.001). Conclusions.: Patients upstaged to Stage IIIC epithelial ovarian cancer for node involvement have an excellent 5-year OS relative to all patients with Stage IIIC disease. These data demonstrate the necessity for stratifying patients classified as having Stage IIIC disease based solely on nodal disease when comparing outcomes. This information is particularly valuable when counseling patients regarding prognosis.

Original languageEnglish (US)
Pages (from-to)797-801
Number of pages5
JournalGynecologic Oncology
Volume103
Issue number3
DOIs
StatePublished - Dec 2006

Fingerprint

Survival
Ovarian epithelial cancer
Surgical Pathology
Pelvis
Counseling
Ovary
Lymph Nodes
Neoplasm Metastasis
Control Groups
Neoplasms

Keywords

  • Lymphadenectomy
  • Ovarian cancer
  • Retroperitoneal dissemination
  • Staging
  • Survival

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only? / Cliby, William Arthur; Aletti, Giovanni D.; Wilson, Timothy O.; Podratz, Karl C.

In: Gynecologic Oncology, Vol. 103, No. 3, 12.2006, p. 797-801.

Research output: Contribution to journalArticle

Cliby, William Arthur ; Aletti, Giovanni D. ; Wilson, Timothy O. ; Podratz, Karl C. / Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only?. In: Gynecologic Oncology. 2006 ; Vol. 103, No. 3. pp. 797-801.
@article{78e77f7f79e14edf955298e2ab541e99,
title = "Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only?",
abstract = "Background.: Stage IIIC epithelial ovarian cancer is generally associated with upper abdominal tumor implants of greater than 2 cm and carries a grave prognosis. A subset of patients is upstaged to Stage IIIC because of lymph node metastases, in which prognosis is not well defined. We undertook this study to describe the clinical behavior of occult Stage IIIC. Methods.: All consecutive patients found to have Stage IIIC epithelial ovarian cancer during a 9-year period (1994-2002) were analyzed for surgical procedures, pathology, and disease-free (DFS) and overall survival (OS). Results.: Thirty-six patients were upstaged to Stage IIIC by virtue of positive nodes. Nine had small volume upper abdominal disease (IIIA/B before upstaging), 15 had disease limited to the pelvis and 12 had disease confined to the ovaries. 32/36 patients had no gross residual disease at the conclusion of surgery. The 5-year DFS and OS survivals were 52{\%} and 76{\%} respectively, for all patients. We observed no significant difference in outcomes between patients upstaged from IIIA/B versus I-II stage disease. The outcomes were superior to a control group of patients cytoreduced to either no gross RD or RD < 1 cm, who had large volume upper abdominal disease at beginning of surgery (p < 0.001). Conclusions.: Patients upstaged to Stage IIIC epithelial ovarian cancer for node involvement have an excellent 5-year OS relative to all patients with Stage IIIC disease. These data demonstrate the necessity for stratifying patients classified as having Stage IIIC disease based solely on nodal disease when comparing outcomes. This information is particularly valuable when counseling patients regarding prognosis.",
keywords = "Lymphadenectomy, Ovarian cancer, Retroperitoneal dissemination, Staging, Survival",
author = "Cliby, {William Arthur} and Aletti, {Giovanni D.} and Wilson, {Timothy O.} and Podratz, {Karl C.}",
year = "2006",
month = "12",
doi = "10.1016/j.ygyno.2006.08.047",
language = "English (US)",
volume = "103",
pages = "797--801",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only?

AU - Cliby, William Arthur

AU - Aletti, Giovanni D.

AU - Wilson, Timothy O.

AU - Podratz, Karl C.

PY - 2006/12

Y1 - 2006/12

N2 - Background.: Stage IIIC epithelial ovarian cancer is generally associated with upper abdominal tumor implants of greater than 2 cm and carries a grave prognosis. A subset of patients is upstaged to Stage IIIC because of lymph node metastases, in which prognosis is not well defined. We undertook this study to describe the clinical behavior of occult Stage IIIC. Methods.: All consecutive patients found to have Stage IIIC epithelial ovarian cancer during a 9-year period (1994-2002) were analyzed for surgical procedures, pathology, and disease-free (DFS) and overall survival (OS). Results.: Thirty-six patients were upstaged to Stage IIIC by virtue of positive nodes. Nine had small volume upper abdominal disease (IIIA/B before upstaging), 15 had disease limited to the pelvis and 12 had disease confined to the ovaries. 32/36 patients had no gross residual disease at the conclusion of surgery. The 5-year DFS and OS survivals were 52% and 76% respectively, for all patients. We observed no significant difference in outcomes between patients upstaged from IIIA/B versus I-II stage disease. The outcomes were superior to a control group of patients cytoreduced to either no gross RD or RD < 1 cm, who had large volume upper abdominal disease at beginning of surgery (p < 0.001). Conclusions.: Patients upstaged to Stage IIIC epithelial ovarian cancer for node involvement have an excellent 5-year OS relative to all patients with Stage IIIC disease. These data demonstrate the necessity for stratifying patients classified as having Stage IIIC disease based solely on nodal disease when comparing outcomes. This information is particularly valuable when counseling patients regarding prognosis.

AB - Background.: Stage IIIC epithelial ovarian cancer is generally associated with upper abdominal tumor implants of greater than 2 cm and carries a grave prognosis. A subset of patients is upstaged to Stage IIIC because of lymph node metastases, in which prognosis is not well defined. We undertook this study to describe the clinical behavior of occult Stage IIIC. Methods.: All consecutive patients found to have Stage IIIC epithelial ovarian cancer during a 9-year period (1994-2002) were analyzed for surgical procedures, pathology, and disease-free (DFS) and overall survival (OS). Results.: Thirty-six patients were upstaged to Stage IIIC by virtue of positive nodes. Nine had small volume upper abdominal disease (IIIA/B before upstaging), 15 had disease limited to the pelvis and 12 had disease confined to the ovaries. 32/36 patients had no gross residual disease at the conclusion of surgery. The 5-year DFS and OS survivals were 52% and 76% respectively, for all patients. We observed no significant difference in outcomes between patients upstaged from IIIA/B versus I-II stage disease. The outcomes were superior to a control group of patients cytoreduced to either no gross RD or RD < 1 cm, who had large volume upper abdominal disease at beginning of surgery (p < 0.001). Conclusions.: Patients upstaged to Stage IIIC epithelial ovarian cancer for node involvement have an excellent 5-year OS relative to all patients with Stage IIIC disease. These data demonstrate the necessity for stratifying patients classified as having Stage IIIC disease based solely on nodal disease when comparing outcomes. This information is particularly valuable when counseling patients regarding prognosis.

KW - Lymphadenectomy

KW - Ovarian cancer

KW - Retroperitoneal dissemination

KW - Staging

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=33751433344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751433344&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2006.08.047

DO - 10.1016/j.ygyno.2006.08.047

M3 - Article

C2 - 17052746

AN - SCOPUS:33751433344

VL - 103

SP - 797

EP - 801

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -